5 EASY FACTS ABOUT LINSITINIB DESCRIBED

The LIDS trial met its Principal endpoint with statistical importance for the 150mg BID dose. Linsitinib During this trial validated the protection profile found inside the prior oncology studies and importantly demonstrated a favorable safety profile on key adverse activities (AEs) of fascination for that IGF-1R concentrate on such as hearing impa